ArticleDiscover oncology2026
A novel mitochondrial-related gene signature for assessing the tumor immune microenvironment and predicting prognosis in human glioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas represent the most prevalent and aggressive primary brain tumors in adults. Accumulating data suggest a strong connection between mitochondrial dysfunction and cancer development. However, signature markers for assessing mitochondrial genetic risk in human glioma remain limited. This study aims to identify mitochondrial genes associated with glioma patient prognosis, develop a strong mitochondrial-related gene signature (MRGS), and analyze the tumor immune microenvironment (TIME) related to this signature. The expression profiles and prognostic value of MRGS were analyzed using R language, GraphPad Prism 8 and online databases.
resultsA signature of seven genes including ACSL1, NOX4, ALDH3A2, ALKBH4, FASTK, FDX1, ACADVL was constructed using the TCGA cohort and further validated in an independent CGGA cohort. Our result showed that the mitochondrial signature was significantly associated with high-grade and isocitrate dehydrogenase (IDH) wild-type gliomas, aggressive molecular and histological features, and poor survival. Subgroup analyses demonstrated that the risk signature was significantly associated with overall survival (OS) across WHO tumor grades and IDH mutation status, suggesting added prognostic value beyond established clinical markers. Additionally, the risk signature demonstrated a significant difference in immune cell infiltration between the high-risk (H-R) and low-risk (L-R) groups. Moreover, the risk score was strongly correlated with tumor microenvironment (TME)-related marker and immune checkpoint molecules such as (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, BTLA, HVEM, NR2F6), suggesting that an immunosuppressive TME could lead to a poor prognosis in H-R groups. Additionally, Multivariable Cox analysis showed that risk score was an independent predictor of poor prognosis in both TCGA (Hazard Ratio (HR) = 2.17, 95% confidence interval (CI): 1.44-3.3, p < 0.001) and CGGA (HR = 2.07, 95% CI: 1.49-2.88 p < 0.001) datasets. Finally, enrichment analysis highlighted the association of the signature with biological mechanisms involved in tumor progression.
conclusionOur findings suggest a novel mitochondrial-related gene signature for the TIME that could be used as a reliable prognostic biomarker for patients with glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.